Progression-Free Survival Increased With Zanubrutinib in Leukemia
Physician's Weekly,
TUESDAY, Jan. 3, 2023 (HealthDay News) — Progression-free survival is significantly longer with zanubrutinib than ibrutinib…
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Overview of attention for article published in New England Journal of Medicine, December 2022
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (99th percentile)
-
High Attention Score compared to outputs of the same age and source (82nd percentile)
Mentioned by
- news
- 63 news outlets
- blogs
- 2 blogs
- policy
- 3 policy sources
- 112 X users
- 1 Facebook page
- wikipedia
- 1 Wikipedia page
- 1 Redditor
- guideline
- 5 clinical guideline sources
- podcasts
- 2 podcasts
Readers on
- mendeley
- 291 Mendeley